Tributyltin and dibutyltin alter secretion of tumor necrosis factor alpha from human natural killer cells and a mixture of T cells and natural killer cells by Hurt, Kelsi et al.
Tennessee State University 
Digital Scholarship @ Tennessee State University 
Chemistry Faculty Research Department of Chemistry 
10-10-2012 
Tributyltin and dibutyltin alter secretion of tumor necrosis factor 
alpha from human natural killer cells and a mixture of T cells and 
natural killer cells 
Kelsi Hurt 
Tennessee State University 
Tasia Hurd-Brown 
Tennessee State University 
Margaret Whalen 
Tennessee State University 
Follow this and additional works at: https://digitalscholarship.tnstate.edu/chemistry-faculty 
 Part of the Cancer Biology Commons, and the Cell Biology Commons 
Recommended Citation 
Hurt, K., Hurd-Brown, T. and Whalen, M. (2013), Tributyltin and dibutyltin alter secretion of tumor necrosis 
factor alpha from human natural killer cells and a mixture of T cells and natural killer cells. J. Appl. 
Toxicol., 33: 503-510. https://doi.org/10.1002/jat.2822 
This Article is brought to you for free and open access by the Department of Chemistry at Digital Scholarship @ 
Tennessee State University. It has been accepted for inclusion in Chemistry Faculty Research by an authorized 
administrator of Digital Scholarship @ Tennessee State University. For more information, please contact 
XGE@Tnstate.edu. 
Tributyltin (TBT) and Dibutyltin (DBT) Alter Secretion of Tumor
Necrosis Factor Alpha (TNFα) from Human Natural Killer (NK)
Cells and a Mixture of T cells and NK Cells
Kelsi Hurt*, Tasia Hurd-Brown*, and Margaret Whalen
*Department of Biological Sciences, Tennessee State University, Nashville, TN, 37209
Department of Chemistry, Tennessee State University, Nashville, TN, 37209
Abstract
Butyltins (BTs) have been in widespread use. Tributyltin (TBT) has been used as a biocide in a
variety of applications and is found in human blood samples. Dibutyltin (DBT) has been used as a
stabilizer in polyvinyl chloride plastics and as a de-worming agent in poultry. DBT, like TBT, is
found in human blood. Human natural killer (NK) cells are the earliest defense against tumors and
viral infections and secrete the cytokine tumor necrosis factor (TNF) alpha (α). TNFα is an
important regulator of adaptive and innate immune responses. TNFα promotes inflammation and
an association between malignant transformation and inflammation has been established.
Previously, we have shown that TBT and DBT were able to interfere with the ability of NK cells
to lyse tumor target cells. Here we show that BTs alter cytokine secretion by NK cells as well as a
mixture of T and NK lymphocytes (T/NK cells). We examined 24 h, 48 h, and 6 day exposures to
TBT (200- 2.5 nM) and DBT (5- 0.05 µM) on TNFα secretion by highly enriched human NK cells
and T/NK cells. The results indicate that TBT (200 - 2.5 nM) decreased TNFα secretion from NK
cells. In the T/NK cells 200 nM TBT decreased secretion while 100-5 nM TBT increased
secretion of TNFα. NK cells or T/NK cells exposed to higher concentrations of DBT showed
decreased TNFα secretion while lower concentrations showed increased secretion. The effects of
BTs on TNFα secretion are seen at concentrations present in human blood.
INTRODUCTION
Tumor necrosis alpha (TNFα) is a cytokine that regulates the function of both the innate and
adaptive immune system. It is initially produced as a 26 kD transmembrane protein that is
then released from the membrane as a 17kD protein. It is secreted by a wide array of cells
including T cells, natural killer (NK) cells, and monocytes (Goetz et al., 2004). It activates
the inflammatory immune response, and is able to causes apoptosis as well as cell
proliferation (Guicciardi and Gores, 2009; Silke, 2011). TNFα is a potent inflammatory
stimulus and as such has the capacity to cause chronic inflammation. There is a well
established connection between chronic inflammation and certain cancers such as
gastrointestinal cancers (Macarthur et al., 2004). Thus, it important that TNFα levels in the
body are carefully regulated to prevent either a loss of immune competency or the risks that
occur due to chronic inflammation.
Natural killer (NK) cells (CD16+/CD56+, CD3−) are the earliest defense against tumors and
viral infections and interference with their function increases susceptibility to cancer and
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viruses (Lotzova, 1993; Lanier., 2008; Kiessling and Haller, 1978; Hanna, 1980; Fleisher et
al., 1982; Biron et al., 1989). Their importance in preventing cancers and viral infections has
been shown both in humans and in animal models (Ortaldo, et al., 1992; Purdy and
Campbell, 2009; Ballas et al., 1990; Fulton et al., 1984; Makrigiannis and Anderson, 2003;
Mishra et al., 2010). They are known to secrete TNFα as well as other cytokines and this is
also a significant part of their important immune function. For instance, secretion of TNFα
by NK cells is important in the maturation of dendritic cells whose antigen presenting
function is needed in the immune response (Andoniou et al., 2008).
The butyltins, (BTs) tributyltin (TBT) and dibutyltin (DBT), have been used in a wide
variety of industrial applications including as an ingredient in antifouling paints (TBT), as
an antifungal agent in a variety of products (TBT), and in the case of DBT as a stabilizer in
plastics (Crowe, 1987; Takahashi et al., 1999; Gipperth, 2009; Roper, 1992; Kannan et al.,
1995). TBT’s use in marine antifouling paints has been banned since 2008 but it will
continue to contaminate the environment for many years due to its chemical stability, non-
marine uses, applications to ships prior to the ban, and marine uses in spite of the ban
(Gipperth, 2009). TBT is found in fish (Kannan et al., 1995) and DBT is found in drinking
water (Sadiki et al., 1996). TBT is found in human blood at levels ranging as high as 261
nM (85 ng/mL) and DBT at levels as high as 300 nM (94 ng/mL) (Whalen et al., 1999;
Kannan et al., 1999). TBT-exposed mammals show increased incidences of tumors (Wester
et al., 1990) and decreased NK cell function (Ghoneum et al., 1990). We have established
that TBT and DBT decrease human NK lytic function, target-binding function, cell-surface
protein expression, and cytolytic protein expression at levels that are in the range found in
human blood (Whalen et al., 1999; Dudimah et al., 2007a,b ,Whalen et al., 2002; Odman-
Ghazi et al., 2003; Thomas et al., 2004; Catlin et al., 2005). A rapid activation of a portion
of the signaling pathway(s) that regulates NK lytic function (beginning with protein kinase
C through mitogen-activated protein kinases (MAPKs)) accompanies the loss of lytic
function (Aluoch and Whalen, 2005; Aluoch et al., 2006; Aluoch et al., 2007; Odman-Ghazi
et al., 2010; Abraha et al., 2010).
Although we have found that both TBT and DBT have dramatic effects on the ability of
human NK cells to destroy tumor cells we have not previously investigated whether these
compounds might also effect the secretion of TNFα by NK cells. TNFα has effects on
immune system cells, as well as on other cell types (Goetz et al., 2004), thus, it essential to
determine if its secretion by NK cells is also altered by exposures to these compounds.
In this study we examined whether exposures of NK cells to TBT and DBT could alter their
secretion of TNFα. In addition to examining the effects of TBT and DBT on the secretion of
TNFα by a highly purified preparation of NK cells, we also looked at their effects on a
preparation that contained both NK cells and T cells. This is a more reconstituted system
which allowed us to examine whether there were differences in the effects of the BTs
between the purified NK system and the more complex system of immune cells.
MATERIALS AND METHODS
Preparation of NK cells
Peripheral blood from healthy adult (male and female) volunteer donors was used for this
study. Buffy coats (source leukocytes) obtained from Key Biologics, LLC (Memphis, TN)
were used to prepare NK cells. Highly purified NK cells were obtained using a rosetting
procedure. Buffy coats were mixed with 0.6–0.8 mL of RosetteSep human NK cell
enrichment antibody cocktail (StemCell Technologies, Vancouver, British Columbia,
Canada) per 45 mL of buffy coat. The mixture was incubated for 25 min at room
temperature (~ 25° C). Following the incubation, 7–8 mL of the mixture was layered onto 4
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mL of Ficoll-Hypaque (1.077 g/mL) (MP Biomedicals, Irvine, CA) and centrifuged at 1200
g for 30–50 min. The cell layer was collected and washed twice with phosphate buffered
saline (PBS) pH 7.2 and stored in complete media (RPMI-1640 supplemented with 10%
heat-inactivated bovine calf serum (BCS), 2 mM L-glutamine and 50 U penicillin G with 50
µg streptomycin/ml) at 1 million cells/mL at 37 °C and air/CO2, 19:1.
Preparation of T/NK cells
Preparations of T cells and NK cells were isolated from Leukocyte filters (PALL- RCPL)
obtained from the Red Cross Blood Bank Facility (Nashville, TN) as described in Meyer et
al., 2005. A unit of blood is put through these filters to remove leukocytes. The leukocytes
can be retrieved from the filters by back-flushing them with an elution medium and
collecting the eluent. The elution medium is sterile PBS containing 5 mM disodium EDTA
and 2.5% [w/v] sucrose. The resulting eluent contains the leukocytes with some red cell
contamination. The eluent is layered onto Ficoll-Hypaque (1.077g/mL) and centrifuged as
described above. The granulocytes and red cells form a pellet at the bottom of the tube while
the lymphocytes and monocytes float on the Ficoll-Hypaque. Mononuclear cells were
collected from the Ficoll-Hypaque and washed twice (250 g, 10 min.) with PBS. The pellet
was resuspended in PBS and the process was repeated. The cells were then suspended in
complete medium which consisted of RPMI-1640 supplemented with 10% heat-inactivated
BCS, 2 mM L-glutamine and 50 U penicillin G with 50 µg streptomycin/mL. Non adherent
cells (10–20% CD16+, 10–20 % CD56+, 70–80% CD3+, 3–5% CD19+, 2–20% CD14+)
were prepared by incubating the cells in glass Petri dishes (150 ×15 mm) at 37 °C and air/
CO2, 19:1 for 1 h. This cell preparation is referred to as T/NK cells.
Chemical preparation
TBT and DBT were purchased from (Sigma-Aldrich, St. Louis, MO). TBT was a neat
standard, dissolved initially in deionized water to give a 1 mM solution. A DBT stock
solution was prepared by dissolving DBT in dimethylsulfoxide (DMSO). Desired
concentrations of either TBT or DBT were prepared by dilution of the stock into complete
media. The final concentration of DMSO for DBT exposures did not exceed 0.01%.
Appropriate DMSO controls were run.
Cell treatments
NK cells or T/NK cells (at a concentration of 1.5 million cells/ mL) were treated with TBT
(or appropriate control) at concentrations of 2.5–200 nM for 24 h, 48 h, or 6 days. Cells
were treated with DBT at concentrations of 0.05–5 µM for the same lengths of incubation as
used with TBT. Following the incubations the cells were pelleted and the supernatants were
collected and frozen at −50°C until assay.
Cell viability
Cell viability was assessed at the beginning and end of each exposure period. Viability was
determined using the trypan blue exclusion method. Briefly, cells were mixed with trypan
blue and counted using a hemocytometer. The total number of cells and the total number of
live cells were determined for both control and treated cells to determine the percent viable
cells. Results are shown in tables 1 and 2.
TNFα secretion assay
Supernatants from cells (exposed as described above) were collected and stored at −50°C
until being assayed for TNFα levels. TNFα levels were measured using the OptEIA™
enzyme-linked immunosorbent assay (ELISA) human TNFα kit (BD-Pharmingen, San
Diego, CA). A 96 well flat-bottom microwell plate specifically designed for ELISA (Fisher,
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St.Louis MO) was coated with capture antibody diluted in coating buffer. The plate was
incubated with the capture antibody overnight at 4°C. Following this incubation the plate
was washed three times with wash buffer (PBS with 0.05% Tween-20). Blocking buffer was
then applied to each well and the plate was sealed and incubated at room temperature for 1
h. The plate was then washed three times and cell supernatants and TNFα standards were
applied to the wells and the plate was sealed and incubated at room temperature for 2 h.
Following the incubation with samples and standards the plate was washed five times and
detection antibody was then added to the wells and incubated for 1 h at room temperature.
Detection antibody was removed by washing 7 times and a substrate solution was added to
each well and incubated for 30 min at room temperature. The absorbance was measured at
450 nm on a Thermo Labsystems Multiskan MCC/340 plate reader (Fisher Scientific).
Statistical analysis
Statistical analysis of the data was carried out utilizing ANOVA and Student's t test. Data
were initially compared within a given experimental setup by ANOVA. A significant
ANOVA was followed by pair wise analysis of control versus exposed data using Student’s
t test, a p value of less than 0.05 was considered significant.
RESULTS
Viability of NK cells exposed to TBT
Table 1 shows that when NK cells were exposed to 2.5–200 nM TBT for 24 h there was no
effect on the viability of the cells as compared to control NK cells. This indicated that there
was not a generalized toxicity of the compound on the cells. A 48 h exposure to these same
concentrations caused a small decrease in viability it at 200 nM TBT (~15%), while all other
concentrations of TBT caused no decrease in viability. A 6 day exposure to 200 nM TBT
also caused some decrease in viability as compared to control cells however no other
concentrations affected viability.
Effects of TBT exposures on secretion of TNFα by NK cells
Highly purified NK cells were exposed to 0, 2.5, 5, 10, 25, 50, 100 and 200 nM TBT for 24
h, 48 h, and 6 days. Following the exposures the supernatants from the cell suspension were
collected and TNFα levels were measure. A minimum of 3 different cell preparations from
different donors were used for each time point. Figure 1 shows the effects of these exposures
in cells prepared from an individual donor. The data indicate that after a 24 h exposure to
TBT there was a significant decrease (p<0.05) in TNFα secretion at all of the concentrations
tested except 2.5 nM. The longer incubations of 48 h and 6 d showed statistically significant
decreases in TNFα secretion only at the 2 highest concentrations of 100 and 200 nM for NK
cells from this donor. In order to combine data from different donors, the secretion of TNFα
in the treated cells were normalized to their respective control cells. The data is presented
then as percent of control secretion of TNF α. Figure 2 shows that when experiments from
different donors were combined that there was a significant decrease in TNFα secretion at
every concentration of TBT when NK cells were exposed for 24h. Exposures to TBT for 48
h or 6 d caused significant decreased in TNFα secretion only at the 2 highest concentrations
of TBT as was seen when looking at data from NK cells from an individual donor.
Viability of T/NK cells exposed to TBT
When T/NK cells were exposed to TBT for 24 h there was a very small effect of the 200 nM
concentration on viability (Table 1). Viability was decreased from 99% in the control to
94% in the cells treated with 200 nM TBT. There was also a decrease in viability with the
200 nM TBT exposure after 48 h. 6 day exposures to both 200 and 100 nM TBT caused a
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decrease in T/NK cell viability (however the majority of cells were viable in both cases)
(Table 1).
Effects of TBT exposures on secretion of TNFα by T/NK cells
As T cells are also able to secrete TNFα, we examined whether their presence in the cell
preparation would alter the effects of TBT on TNFα secretion from that seen with purified
NK cells. Although we refer to this preparation as T/NK cells there were also some
monocytes in the preparation (although they had been significantly depleted). The T/NK cell
preparation was treated with 2.5, 5, 10, 25, 50, 100 and 200 nM TBT for 24 h, 48 h, and 6
days and TNFα levels in the supernatants from these incubations were measured. The data
from cells prepared from an individual donor are shown in Figure 3. As was seen with the
purified NK cells, exposure to 200 nM TBT for 24 h caused a nearly complete loss of TNFα
secretion. However, a 24 h exposure to 25, 50, and 100 nM TBT caused significant increases
in TNFα secretion as compared to the control cells. The greatest increase (2.16 fold) was
seen with a 100 nM TBT exposure. A 48 h exposure to TBT also caused an essentially
compete block of TNFα secretion from T/NK cells. Exposure from 5 –100 nM caused
significant increases in the secretion of TNFα from the T/NK cell preparation. A 48 h
exposure to 50 nM TBT caused the greatest fold increase (3.4 fold) above control cells. The
effect of 6 d exposures to TBT in the cells from this donor looked very similar to what was
seen at 48 h (Figure 3). The effects on TNFα secretion seen when the data from all donors
was combined (as described above) is shown in Figure 4. As was seen with the purified NK
cells an exposure to 200 nM TBT for 24 h decreased the secretion of TNFα from the T/NK
cells almost completely. However, concentrations of TBT from 10 to 100 mM all caused
significant increases in secretion of TNFα when data was combined as compared with the
effects seen in cells from an individual donor where 25 nM was the lowest concentration to
cause a significant increase. The greatest increase was seen at 100 nM in the combined data
as was true in the data from an individual, however the average fold increase was somewhat
higher at 3.5 fold (Figure 4). When data from all experiments were combined the 48 h
exposures to TBT showed increases at 5 to 100 nM (Figure 4). Unlike the 24 h exposures
there was no significant decrease at the 200 nM exposure, this was due to the large
variability of the results from cells isolated from different donors. The greatest average
increase in TNFα secretion seen at 48 h in the combined data was also at the 100 nM
concentration (average of 7.6 fold). Again, there was a large amount of variation from one
donor to the next under this condition, with the lowest increase being 3 fold and the highest
increase 18 fold. Result of the combined experiments after a 6 d exposure were similar to
those seen at 48 h only the fold increases were considerably lower that they were at 48 h
(Figure 4).
Viability of NK cells exposed to DBT
NK cells exposed to DBT for 24 h showed decreased viability compared to control cells at
the 5 and 2.5 µM concentrations. The decreases were small with the 5 µM DBT showing
84% viability while control cells were 95% viable. Cells exposed to 2.5 µM DBT for 24 h
were 86% viable as compared to controls (95%) (Table 2). Viability of NK cells exposed to
5, 2.5, 1, and 0.5 µM DBT for both 48 h and 6 days was somewhat decreased as compared to
controls (Table 2).
Effects of DBT exposures on secretion of TNFα by NK cells
Figure 5 shows the effects of exposures to 0, 0.05, 0.1, 0.25, 0.5, 1, 2.5, and 5 µM DBT for
24 h, 48 h, and 6 d on highly purified NK cells prepared from an individual donor. After a
24 h exposure to DBT there was a complete loss of TNFα secretion at 0.5 to 5 µM DBT
exposures (P<0.05). There was also a significant decrease of about 20% at the 0.25 µM
exposure. The lower concentrations of DBT 0.05 and 0.1µM each caused an increase in
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secretion of TNFα as compared to control cell after a 24 h exposure (1.6 and 1.7 fold,
respectively) (Figure 5). 48 h exposures to 0.5 to 5 µM DBT caused a total loss of TNFα
secretion from highly purified NK cells from this individual. Exposure to 0.25 µM DBT
caused no significant change in TNFα secretion while 0.05 and 0.1 µM DBT caused
increases in TNFα secretion of 1.8 and 1.9 fold, respectively (Figure 5). Exposure to 0.25 to
5 µM DBT for 6 d completely blocked TNFα secretion in the NK cells from this donor
while 0.1 µM DBT caused an approximately 4 fold increase in secretion and 0.05 µM caused
no significant change as compared to the control cells (Figure 5). As described above, data
from different donors was combined by normalizing the secretion seen at each of the
treatments to their respective control cells and then combining the data as percent of control
secretion of TNFα. Figure 6 shows that when experiments from different donors were
combined that the decreases were similar to those seen in the individual experiment for cells
exposed to DBT for 24h. Exposures to DBT for 48 h caused a total block in TNFα secretion
at 0.5 to 5 µM and significant increases at 0.1 and 0.05 µM DBT. These increases averaged
around 2 fold (Figure 6), which was similar to the increase seen in the individual experiment
(Figure 5). 6 d exposures to DBT in the combined experiments showed the same general
trends as were seen with the individual experiment but with a much larger variability (Figure
6).
Viability of T/NK cells exposed to DBT
Table 2 shows the effects of 5–0.05 µM DBT exposures for 24 h, 48 h, and 6 days on the
viability of T/NK cells. The results for TNK cells were very similar to those seen with
highly purified NK cells (Table 2).
Effects of DBT exposures on secretion of TNFα by T/NK cells
Figure 7 shows the effects of exposures to 0, 0.05, 0.1, 0.25, 0.5, 1, 2.5, and 5 µM DBT for
24 h, 48 h, and 6 d on T/NK cells prepared from an individual donor. A 24 h exposure to
DBT caused a complete loss of TNFα secretion at 2.5 and 5 µM DBT exposures (P<0.01).
Concentrations of DBT 0.1, 0.25, and 0.5µM each caused an increase in secretion of TNFα
as compared to control cells after a 24 h exposure (1.6 fold at 0.1 µM; 2.3 fold at 0.25 µM
and 2.7 fold at 0.5 µM, p<0.01 for all values) (Figure 7). 48 h exposures to 2.5 and 5 µM
DBT caused an essentially total loss of TNFα secretion from T/NK cells in this individual.
In contrast, exposures to 0.05 up to 1 µM DBT each caused significant increases in TNFα
secretion. The fold increases were as follows: 2.7 fold at 0.05 µM (p<0.05) ; 3.6 fold at 0.1
µM (p<0.01); 9.2 fold (p<0.01) at 0.25 µM; 8.2 fold at 0.5 µM (p<0.01) and 2.9 fold at 1 µM
(p<0.02) (Figure 7). A 6 day exposure to 2.5 to 5 µM DBT for 6 d completely blocked
TNFα secretion in the T/NK cells from this donor while 1 µM DBT caused a 38% decrease
in secretion (p<0.001 in all cases) (Figure 7). Exposure to 0.05 µM DBT increased secretion
of TNFα by 2.6 fold (p<0.05), 0.1, 0.25, and 0.5 µM DBT caused increases of 3.4, 7.9, and
7.6 fold, respectively (p<0.01) (Figure 7). Figure 8 shows that when experiments from
different donors were combined that the decreases were similar to those seen in the
individual experiment for cells exposed to 2.5 and 5 µM DBT at each of the lengths of
exposure. The increases in TNFα secretion seen with exposures to 0.05 up to 0.5 µM DBT
in the individual were also seen in all other donors although the magnitude of the increase
varied among donors (Figure 8).
DISCUSSION
TNFα is an inflammatory cytokine and contributes to many of the negative effects seen with
chronic inflammation. Elevated levels of TNFα are associated with rheumatoid arthritis,
Crohn’s disease and the wasting seen with cancer (Shurety et al., 2000). TNFα is produced
by NK cells, T cells, and monocytes (Goetz et al., 2004). In monocytes, TNFα stimulates
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their cytotoxicity against targets as well as their ability to synthesize more TNFα (Philip et
al., 1986). As mentioned in the introduction, TNFα is synthesized as a 26 kD
transmembrane protein that is then released from the membrane as a 17kD protein (Goetz et
al., 2004). Release from the membrane is catalyzed by membrane-associated
metalloproteinases such as TNFα converting enzyme (TACE) (Black, R.A., et al., 1997).
TNFα also effects lipid metabolism (Chen et al., 2009) and may have a significant role in
insulin resistance seen in obesity (Goetz et al., 2004).
Due to its importance in regulating both immune and other cellular functions, it is important
to determine whether environmental contaminants, especially those found in human blood
and tissues such as the BTs (Whalen et al., 1999; Kannan et al., 1999), are able to effect the
secretion of this potent regulator. Thus, the current study examines the effects of both TBT
and DBT on the ability of immune system cells to secrete TNFα.
The effects of both BTs (TBT and DBT) differed depending on the cell population tested.
When highly purified NK cells were exposed to TBT for 24 h there was a decrease in their
ability to secrete TNFα at every concentration tested and this decrease was not due to a
generalized toxicity of TBT as cell viability was unaffected by the TBT exposures (Table 1).
Concentrations as low as 2.5 nM caused on average a 20% decrease in secretion and this
was seen at levels of TBT of 50-5 nM as well. This same general pattern of effect on TNFα
secretion maintained out to 6 days of exposure to TBT (Figure 2). When a cell preparation
that was primarily T and NK cells (T/NK cells) was exposed to TBT for 24 h, a markedly
different effect on TNFα secretion was seen (Figure 4). There was a decrease in secretion of
TNFα at the 200 nM exposure to TBT, but there was a significant increase in TNFα at 5–
100 nM exposures to TBT. The increases averaged about 5 fold at the 50 and 100 nM
exposures to TBT, 3 fold at 25 nM, and 2 fold at both 5 and 10 nM. The concentrations of
TBT that dysregulate TNFα secretion in both purified NK cells and in T/NK cells are well
below concentrations of TBT that have been found in some human blood samples (Whalen
et al., 1999; Kannan et al., 1999). Levels detected in human blood ranged from undetectable
to about 260 nM, with 69% of the 38 samples tested showing levels of 10 nM and above.
Here we see decreases in TNFα secretion of 20% at 10 nM TBT from NK cells and
increases of 2 fold in secretion from T/NK cells. Thus, the effects on TNFα secretion seen
in these studies have implications for individuals exposed to TBT. Decreases in TNFα
secretion seen in TBT-exposed purified NK cells indicates the potential for a deficit in NK-
mediated signaling to other immune cells in TBT-exposed individuals, such as the
maturation of dendritic cells whose antigen presenting function is needed in the immune
response (Andoniou et al., 2008). Increases in TNFα secretion as were seen when T cells are
present suggests that TBT has the capacity to aberrantly stimulate the inflammatory
response. Inappropriate increases in inflammatory factors such as TNFα lead to a number of
diseases including rheumatoid arthritis, Crohn’s disease, insulin resistance, and cancer
(Shurety et al., 2000; Chen et al., 2009; Grivennikov and Karin, 2012).
Exposure of purified NK cells to DBT for 24 h caused a nearly complete block of TNFα
secretion when the concentrations of DBT were 0.5 to 5 µM. Although there was a small
decrease in NK cell viability at the 2.5 and 5 µM exposures (Table 2) the decrease was not
large enough to account for the complete loss of TNFα secretion seen at these exposures.
Further, a complete block of TNFα secretion was seen at the 0.5 and 1 µM DBT with no
decrease in cell viability (Table 2). Thus, decreases in TNFα secretion seen at 24 h were not
due to a generalized toxicity of DBT. Exposure to 0.25 µM DBT caused significant
decreases in TNFα secretion which was averaged 35%. In contrast to TBT, exposures of
purified NK cells to 0.05 and 0.1 µM DBT for 24 h caused significant increases in TNFα
secretion (1.4 and 1.5 fold, respectively). Exposures of purified NK cells to 0.5 to 5 µM
DBT for 48 h prevented secretion of TNFα, while exposures to 0.05 and 0.1 µM DBT
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increased secretion (0.05 µM averaged 2.3 fold, 0.1 µM averaged 2.2 fold). The pattern of
TNFα secretion after 6 day exposures to DBT was similar to that seen at the other lengths of
exposure except that no significant increases were seen with exposures of 0.05 and 0.1 µM
DBT. When T/NK cells were exposed to DBT at the same concentrations there was an
increase in TNFα secretion in response to 0.05 (on average 3.5 fold after 24 h), 0.1 (on
average 5.3 fold, after 24 h), 0.25 (on average 5.0 fold, 24 h), and 0.5 µM DBT (on
average3.2 fold) while highly purified NK cells only showed increases (which were much
smaller) at the 0.05 and 0.1 concentrations of DBT. DBT levels measured in human blood
range from undetectable to 0.310 µM (Whalen et al., 1999; Kannan et al., 1999). Of the 38
individuals examined 79% had levels at 0.01 µM or above with 34% having levels of 0.025–
0.31 µM. We saw very significant increases in TNFα secretion from T/NK cells in this
concentration range. Thus, as with TBT, very significant increases of TNFα secretion are
occurring at levels of DBT that are found in a significant proportion of human blood
samples. Again, these increases in TNFα secretion could increase the incidence of
inappropriate inflammation in DBT-exposed individuals, which could result in the diseases
mentioned above in the discussion of TBT elevations of TNFα secretion. Thus, the current
data have implications for the effect of demonstrated DBT exposures on human health.
The current study indicates that both BTs have very significant effects on TNFα from
human white blood cells. They show that these contaminants are able to both block and
stimulate the secretion of TNFα and that this is dependent on the composition of the cell
population being tested. TBT caused decreased secretion of TNFα when a highly enriched
population of NK cells was tested while DBT decreased secretion at higher concentrations
and increased it at lower concentrations in this cell preparation. Both BTs were able to
stimulate secretion of TNFα at certain levels in a more complex mixture of cells (which was
predominantly T cells and NK cells). The results indicate the other cell types have a
response to BT exposures that is distinct from that of the NK cells. It will be important to
further investigate the mechanisms of regulation of TNFα secretion in both the NK cells and
T cells (and possibly monocytes) in future studies.
In our previous studies of the effect of BTs on NK cells, we have shown that both TBT and
DBT are able to activate mitogen-activated protein kinases (Aluoch and Whalen, 2005;
Aluoch et al., 2006; Aluoch et al., 2007; Odman-Ghazi et al., 2010). Both ERK1/2 and p38
have been shown to be activated by BTs (Aluoch and Whalen, 2005; Aluoch et al., 2006;
Aluoch et al., 2007; Odman-Ghazi et al., 2010). p38 activation has been shown to stabilize
TNF mRNA in myeloid cells (Mahtani et al., 2001) and to increase TNFα mRNA
translation in murine dendritic cells (Gais et al., 2010). Thus, it is possible that a part of the
mechanism by which BTs are increasing TNFα secretion is due to their effect on p38
activation. Activation of ERK1/2 (p44/42) has also been shown to play a role in secretion of
TNFα from rat Kupffer cells (Cubero, F.J., Nieto, N. 2012)
The current study shows that secretion of TNFα is altered by BT exposures. It will be
important to determine whether this effect is on secretion only or also on production of the
TNFα protein by the immune cells. It has been shown in a murine macrophage cell line that
TBT exposures increased the levels of TNF alpha mRNA (Nakano et al. 2004).
Additionally, TBT could be effecting the function of membrane metalloproteinases such as
TACE which will also need to be examined in the future.
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Secretion of TNFα in pg/mL from purified human NK cells from an individual donor
exposed to tributyltin for 24h, 48 h, and 6 days. NK cells were exposed to concentrations of
TBT of 0, 2.5,5, 10, 25, 50, 100, and 200 nM for 24 h, 48, h or 6 days. Data are the secretion
of TNFα in pg/mL from the cells of an individual donor. Each sample was tested in
triplicate (n=3). Values are mean±S.D at each concentration for each length of incubation.
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Secretion of TNFα (as percent of control) from purified human NK cells exposed to
tributyltin for 24h, 48 h, and 6 days. Concentrations of TBT were the same as in Figure 1.
Data were combined from NK cells from a minimum of 3 different donors (n=9). In order to
combine data from different donors, the secretion of TNFα in the treated cells were
normalized to their respective control cells. The data is presented as percent of control
secretion of TNF α. Values are mean±S.D., * indicates a significant difference from control
values (control arbitrarily = 100%), p<0.05.
Hurt et al. Page 13














Secretion of TNFα in pg/mL from a mixture of human T and NK cells from an individual
donor exposed to tributyltin for 24h, 48 h, and 6 days. NK cells were exposed to
concentrations of TBT of 0, 2.5,5, 10, 25, 50, 100, and 200 nM for 24 h, 48, h or 6 days.
Data are the secretion of TNFα in pg/mL from the cells of an individual donor. Each sample
was tested in triplicate (n=3). Values are mean±S.D at each concentration for each length of
incubation.
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Secretion of TNFα (as percent of control) from a mixture of human T and NK cells exposed
to tributyltin for 24h, 48 h, and 6 days. Concentrations of TBT were the same as in Figure 3.
Data were combined from NK cells from a minimum of 3 different donors (n=9). In order to
combine data from different donors, the secretion of TNFα in the treated cells were
normalized to their respective control cells. The data is presented as percent of control
secretion of TNF α. Values are mean±S.D., * indicates a significant difference from control
values (control arbitrarily = 100%), p<0.05.
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Secretion of TNFα in pg/mL from purified human NK cells from an individual donor
exposed to dibutyltin for 24h, 48 h, and 6 days. NK cells were exposed to concentrations of
DBT of 0, 0.05, 0.1, 0.25, 0.5, 1, 2.5 and 5 µM for 24 h, 48, h or 6 days. Data are the
secretion of TNFα in pg/mL from the cells of an individual donor. Each sample was tested
in triplicate (n=3). Values are mean±S.D at each concentration for each length of incubation.
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Secretion of TNFα (as percent of control) from purified human NK cells exposed to
dibutyltin for 24h, 48 h, and 6 days. Concentrations of DBT were the same as in Figure 5.
Data were combined from NK cells from a minimum of 3 different donors (n=9). In order to
combine data from different donors, the secretion of TNFα in the treated cells were
normalized to their respective control cells. The data is presented as percent of control
secretion of TNF α. Values are mean±S.D., * indicates a significant difference from control
values (control arbitrarily = 100%), p<0.05.
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Secretion of TNFα in pg/mL from a mixture of human T and NK cells from an individual
donor exposed to dibutyltin for 24h, 48 h, and 6 days. NK cells were exposed to
concentrations of DBT of 0, 0.05, 0.1, 0.25, 0.5, 1, 2.5 and 5 µM for 24 h, 48, h or 6 days.
Data are the secretion of TNFα in pg/mL from the cells of an individual donor. Each sample
was tested in triplicate (n=3). Values are mean±S.D at each concentration for each length of
incubation.
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Secretion of TNFα (as percent of control) from a mixture of human T and NK cells exposed
to dibutyltin for 24h, 48 h, and 6 days. Concentrations of DBT were the same as in Figure 5.
Data were combined from NK cells from a minimum of 3 different donors (n=9). In order to
combine data from different donors, the secretion of TNFα in the treated cells were
normalized to their respective control cells. The data is presented as percent of control
secretion of TNF α. Values are mean±S.D., * indicates a significant difference from control
values (control arbitrarily = 100%), p<0.05.
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